Ozempic and Wegovy: Differentiated FDA Approvals for Diabetes and Weight Management in Tampa
In Tampa, patients seeking weight loss solutions are increasingly encountering semaglutide, the active ingredient in both Ozempic and Wegovy. However, a critical distinction exists in their FDA approvals: Ozempic is approved for adults with type 2 diabetes, while Wegovy holds an FDA indication for long-term weight management in adults with obesity or overweight with at least one weight-related condition, both to be used in conjunction with a reduced-calorie diet and increased physical activity. This difference impacts prescription practices, insurance coverage, and overall care plans. While Ozempic can lead to weight loss due to its mechanism of slowing stomach emptying and promoting satiety, it is not officially indicated for this purpose. Patients are advised to seek a medical evaluation to determine the appropriate medication and to understand the differences between FDA-approved products and compounded semaglutide, which is not reviewed by the FDA in the same manner. Common side effects for semaglutide...
